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Candice Clarke3, Betty P C Lin2, Mark Molloy5, Pierre H Chapuis6, Les Bokey6, Owen F Dent6* and Stephen J Clarke7Abstract
Background: This study examined the association between overall survival and Glutathione S-transferase Pi (GST Pi)
expression and genetic polymorphism in stage C colon cancer patients after resection alone versus resection plus
5-fluourouracil-based adjuvant chemotherapy.
Methods: Patients were drawn from a hospital registry of colorectal cancer resections. Those receiving
chemotherapy after it was introduced in 1992 were compared with an age and sex matched control group from
the preceding period. GST Pi expression was assessed by immunohistochemistry. Overall survival was analysed by
the Kaplan-Meier method and Cox regression.
Results: From an initial 104 patients treated with chemotherapy and 104 matched controls, 26 were excluded
because of non-informative immunohistochemistry, leaving 95 in the treated group and 87 controls. Survival did
not differ significantly among patients with low GST Pi who did or did not receive chemotherapy and those with
high GST Pi who received chemotherapy (lowest pair-wise p = 0.11) whereas patients with high GST Pi who did not
receive chemotherapy experienced markedly poorer survival than any of the other three groups (all pair-wise
p <0.01). This result was unaffected by GST Pi genotype.
Conclusion: Stage C colon cancer patients with low GST Pi did not benefit from 5-fluourouracil-based adjuvant
chemotherapy whereas those with high GST Pi did.
Keywords: Colon cancer, GST Pi, Adjuvant chemotherapy, SurvivalBackground
Glutathione S-transferase Pi (GST Pi) is found in the cell
nucleus, cytoplasm and mitochondria of a wide range of
normal and neoplastic tissues and is expressed in colo-
rectal cancer [1,2]. Elevated GST Pi is associated with
poor prognosis in many cancers, including colorectal
cancer [3,4]. Previously we have shown a high level of
expression of GST Pi to be associated with adverse
histological features and diminished overall survival after
adjustment for other prognostic factors in a large series
of patients who had a potentially curative resection for
stage C colonic adenocarcinoma [5]. That study and* Correspondence: Owen.Dent@netspeed.com.au
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reproduction in any medium, provided the ormany others in colorectal cancer have been prognostic
rather than predictive in that they have examined GST
Pi in consecutive patients who have received the same
treatment or mix of treatments, without random alloca-
tion to different treatment groups. Predictive biomar-
kers, on the other hand, can indicate the likely effect of
specific adjuvant treatment on patient outcomes such as
tumour recurrence or survival.
In colorectal cancer, the prognostic or predictive value
of GST Pi expression or genomic polymorphisms for
outcomes after chemotherapy has been examined in sev-
eral studies. However, in most cases, the patients had
received palliative treatment for advanced metastatic dis-
ease rather than adjuvant treatment in earlier stages and
in most reports there was no random allocation to dif-
ferent treatments. Overall, there is some evidence forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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its predictive ability.
As far as we are aware, there has not yet been any at-
tempt to determine whether GST Pi expression or geno-
type can predict response to adjuvant chemotherapy in
stage III patients with colon cancer, yet this is the group
of patients for whom adjuvant chemotherapy has most
clearly been demonstrated as beneficial in randomised
controlled trials [6]. If biomarkers able to predict the
results of chemotherapy were found, this could lead to
more accurate targeting of treatment to those stage C
patients most likely to benefit and to avoidance of in-
appropriate treatment, with its costs and possible tox-
icity, in those unlikely gain any advantage.
The ability of a tumour marker to predict response to
chemotherapy cannot be determined from a patient
series in which some patients were specifically selected
for chemotherapy and others were not. At first glance
one might simply search for a statistical interaction be-
tween the marker and chemotherapy by comparing out-
come in four categories of patients: those with a low (or
negative) value of the marker who did versus did not re-
ceive chemotherapy and those with a high (or positive)
value who did versus did not receive chemotherapy.
However this would fail to take account of the factors
leading to selection or rejection for chemotherapy,
which are themselves likely to be associated with sur-
vival potential. Comorbidity and advanced tumour stage,
for example, are likely to militate against treatment but
also to be associated with diminished survival. The ideal
research design for identifying the predictive ability of a
marker would certainly involve searching for a statistical
interaction effect among the four groups defined above,
but the patients would need to have been randomly allo-
cated to chemotherapy treatment versus surgery alone
[7]. For ethical reasons, because chemotherapy is cur-
rently given routinely to a large proportion of stage C
colon cancer patients, it is extremely unlikely that such a
randomised trial could now be conducted. An alternative
would be to use data from a historical randomised trial
with the addition of results for a marker obtained by
retrospective histopathological assessment of archived
tissue, although this approach is very rare. An example
of such a research design is the report by McLornan
et al., although that study showed no significant effect
from chemotherapy [8].
Using a prospective hospital-based registry of resec-
tions for colorectal cancer we were able to construct a
historical control group of patients who had a resection
for stage C colonic cancer before chemotherapy was
introduced in our hospital in April 1992 and who could
be matched with patients from May 1992 to December
2004 who did receive chemotherapy. We acknowledge
that this is less than ideal but it is a reasonable surrogatedesign which can yield legitimate information about the
interaction between GST Pi and 5-fluourouracil (5-FU)
based chemotherapy in relation to overall survival and it
is a feasible design which could be used by others with
access to a large historical database and archival tissue
bank for colorectal cancer.
The aim of this study was to examine the association
between GST Pi expression and overall survival in
patients who had received adjuvant chemotherapy after
resection of a stage C colon cancer between May 1992
and December 2004 and an age- and sex-matched his-
torical control group of equivalent patients who had
been treated by surgery alone before the introduction of
adjuvant chemotherapy. A secondary aim was to exam-
ine the survival of these patients according to GST Pi
genotype.Results
Between May 1 1992, when adjuvant chemotherapy was
introduced in this hospital, and December 31 2004
resections for stage C colon cancer were performed on
263 patients, of whom 104 (40%) received adjuvant
chemotherapy. The proportion receiving chemotherapy
increased steadily from 11% in 1992 to 71% in 2004.
One hundred and four age- and sex-matched controls
were selected from among patients who had a resection
for colon cancer between January 1979 and April 1992.
Of the total of 208 patients, 26 had insufficient archived
tissue for immunohistochemical evaluation, leaving 182;
comprising 95 in the chemotherapy group and 87 in the
control group. Fifty-two percent in both groups were
male and mean ages were 64.1 years (SD 9.5) in the
chemotherapy group and 63.6 (SD 10.6) in the control
group (Table 1). There was no significant difference be-
tween the two groups on any of the 10 pathological
characteristics examined in Table 1.
In our earlier detailed study of the prognostic value of
GST Pi we showed that the percentage of cells with nu-
clear staining in the central part of the tumour was the
single best measure of GST Pi expression as an inde-
pendent predictor of overall survival, the optimum cut-
ting point for defining high versus low GST Pi being ≤
40% versus >40% [5]. At this cutting point in the
present study high GST Pi occurred in 63 out of 182
patients (35%). In the chemotherapy group 40% of
patients had high GST Pi as compared with 29% in the
control group, the difference being non-significant
(p = 0.11).
The policy of the database is to follow patients yearly
for up to 14 completed years. At the time of analysis, 98
patients had died, 3 had been lost to follow-up, 24 had
completed 14 years of follow-up and follow-up was con-
tinuing for 57. In patients who had not died (including
Table 1 Background characteristics and tumour
pathology in patients who received adjuvant






Age (mean, SD) 64.1 (9.5) 63.6 (10.6) –
Male 49 (52) 45 (52) –
Tumour site right colon 50 (53) 40 (46) 0.37
Size≥ 5 cm 43 (45) 43 (49) 0.57
Tumour spread beyond
muscularis propria
84 (88) 80 (92) 0.43
Mucinous or signet ring
adenocarcinoma
16 (17) 10 (12) 0.30
≥ 4 lymph nodes involved 26 (27) 26 (30) 0.70
Apical node involved 11 (12) 11 (13) 0.83
High grade tumour 34 (36) 31 (36) 0.98
Venous invasion present 20 (21) 23 (26) 0.39
Free serosal surface involved 22 (23) 23 (26) 0.61
Adjacent structure infiltrated 6 (6) 4 (5) 0.75*
*Fisher’s exact test.
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High GST Pi with chemotherapy
Low GST Pi with chemotherapy
Low GST Pi no chemotherapy
High GST Pi no chemotherapy
Number at risk
38 38 34 33 32 20 20 10 7 5 5
57 57 52 44 42 36 32 27 22 18 11
62 57 52 46 42 38 33 32 29 28 27
25 24 16 11 8 6 6 6 5 5 5
Months
Figure 1 Overall survival by patient group and GST Pi
expression. Overall survival in four patient groups: those with high
GST Pi who received adjuvant chemotherapy, those with low GST Pi
who received chemotherapy, those with low GST Pi who did not
receive chemotherapy, and those with high GST Pi who did not
receive chemotherapy. Differences between the first three groups
were not statistically significant (lowest p = 0.11) whereas differences
between all of those groups and the fourth group were significant
(all p< 0.01).
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280 months with a median of 126 months.
In the overall pool of 182 patients, survival was signifi-
cantly poorer in those who had not received chemother-
apy than in those who had (hazard ratio [HR] 1.8, 95%
confidence interval [CI] 1.2–2.8, p = 0.005). It would not
be meaningful to draw a similar overall comparison be-
tween patients with low and high GST Pi because of the
potential for chemotherapy to attenuate the association
between GST Pi and survival in the chemotherapy
group. However, in patients who had not received
chemotherapy, overall survival was significantly poorer
among those with high central nuclear GST Pi than
among those with low GST Pi (HR 2.3, CI 1.4–3.9,
p = 0.002). Analysis of survival stratified by both high
versus low GST Pi and chemotherapy versus no chemo-
therapy showed no significant difference among patients
with low GST Pi who did or did not have chemotherapy
and those with high GST Pi who had chemotherapyTable 2 Five-year overall Kaplan-Meier survival rates for
stratified analysis of chemotherapy group versus control




Low GST Pi with chemotherapy 68 (55–79)
Low GST Pi without chemotherapy 61 (48–72)
High GST Pi with chemotherapy 69 (52–82)
High GST Pi without chemotherapy 24 (10–42)(lowest p = 0.11) whereas patients with high GST Pi who
did not have chemotherapy experienced significantly
poorer survival than any of the other groups (all p<
0.01) (Table 2, Figure 1). This was corroborated by Cox
regression modelling where high GST Pi and absence of
chemotherapy were coded 2 and the alternatives were
coded 1. The product of these two variables showed a
statistically significant interaction (p = 0.008). Further-
more the interaction term remained statistically signifi-
cant (p< 0.001) when it was included in a model with
all variables in Table 1 that had a bivariate p value of
≤ 0.1 with overall survival (Table 3). Thus, while low
GST Pi was not associated with any difference in re-
sponse to chemotherapy, high GST Pi in the absence of
chemotherapy predicted a markedly poorer outcome
than might otherwise be expected. The implication is
that patients with low GST Pi did not benefit from 5FU-
based chemotherapy whereas those with high GST Pi
clearly did.
The determination of genotype was uninformative in
13 specimens, leaving 169 for analysis; 81 (48%) having









GST Pi by chemotherapy interaction – – 1.4 (1.2–1.8) <0.001
Male sex 1.0 0.850 – –
Age≥ 75 years 1.7 0.044 1.5 (0.9–2.6) 0.153
Right colon tumor 0.7 0.063 0.8 (0.5–1.3) 0.431
Size≥ 5 cm 1.3 0.193 – –
Spread beyond muscularis propria 3.0 0.030 1.6 (0.6–4.6) 0.356
Mucinous or signet ring 1.1 0.730 – –
≥ 4 lymph nodes involved 2.5 <0.001 1.5 (0.97–2.4) 0.071
Apical node involved 2.8 <0.001 2.0 (1.1–3.5) 0.021
High grade tumor 2.3 <0.001 1.7 (1.1–2.7) 0.016
Venous invasion present 1.5 0.084 1.2 (0.8–1.9) 0.418
Free serosal surface involved 3.3 <0.001 2.0 (1.2–3.1) 0.004
Adjacent structure infiltrated 1.3 0.455 – –
* Hazard ratio.
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15 (9%) the Val/Val genotype, which was similar to other
studies [9-11]. The frequency of high GST Pi did not dif-
fer significantly by genotype (Ile/Ile 41%, Ile/Val 29%,
Val/Val 33%; p = 0.295) and there was no difference in
the proportions of patients receiving chemotherapy (Ile/
Ile 44%, Ile/Val 51%, Val/Val 40%; p = 0.637). There was
no overall association between genotype and survival (all
pair-wise p> 0.15) and no association between genotype
and survival in the chemotherapy group alone (all pair-
wise p> 0.42) or in the control group alone (all pair-
wise p> 0.13). When the joint association between
chemotherapy, GST Pi and survival shown in Figure 1
was further stratified by genotype it was again found
that, for patients with the Ile/Ile genotype, those with
high GST Pi who did not receive chemotherapy had sig-
nificantly poorer survival than the other three groups
(all pair-wise p <0.003) and there were no significant
differences among those three groups (all pair-wise p>
0.385). The same was true for the Val/Val genotype (the
corresponding pair-wise p values were p <0.046 and
> 0.527) and there was a non-significant tendency to-
wards the same pattern for the Ile/Val genotype, where
there were only nine patients in the high GST Pi/no
chemotherapy group. From these results it was con-
cluded that genotype had no influence on the association
between survival and the joint effects of chemotherapy
and GST Pi expression.
Discussion
GST Pi is a member of the glutathione-S-transferase
superfamily of phase II xenobiotic-metabolizing enzymes
that catalyse the conjugation of endogenous and exogen-
ous electrophiles, including reactive oxygen species,toxins, carcinogens and anti-cancer agents, to the nu-
cleophilic thiol group of reduced glutathione (GSH) [12].
A number of studies have concentrated on the connec-
tion between aberrant expression of GST isozymes, in-
cluding GST Pi isozymes, with the development and
expression of resistance to chemotherapy drugs as
reviewed by McIlwain et al. [13]. From this perspective
an expected result should have been a poor response to
chemotherapy in patients with high expression of GST
Pi. However our study has shown that, for stage C colon
cancer patients, overall survival was significantly and
markedly poorer in patients with high GST Pi who did
not receive chemotherapy than in those with high GST
Pi who did. Furthermore, survival in the latter group
was no different from that in patients with low GST Pi,
whether or not they received chemotherapy. Expressed
differently, chemotherapy had no apparent effect on sur-
vival in patients with low GST Pi whereas those with
high GST Pi appeared to benefit considerably. This find-
ing could be explained by the fact that a major function
of GST Pi is not only the phase II metabolism of drugs
but to also contribute to the detoxification of endogen-
ously generated reactive oxygen species and the asso-
ciated potentially toxic macromolecules and lipid
peroxides produced in cells. An example of this detoxifi-
cant/antioxidant role is the induction of GST Pi as part
of the coordinated defence mechanism to protect co-
lonic cells against oxidative injury [14]. The presence of
high GST Pi in colon tumours may confer a selective ad-
vantage on malignant colon cells, as increased produc-
tion of reactive oxygen species is a feature of cancer
progression [15]. Therefore the poorer overall survival in
patients with high GST Pi who did not receive chemo-
therapy could be attributed to the ability of GST Pi to
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ence of malignant colon cells and thereby leading to
poorer survival. This is also consistent with our previous
finding of increased GST Pi expression being an inde-
pendent prognostic factor for reduced overall survival
[5]. Furthermore, treatment with diverse chemotherapy
drugs tips the redox balance of already stressed cancer
cells and elicits selective additional toxicity that ultim-
ately kills them. In this regard the recent reports of the
ability of 5-FU to promote oxidative stress in colonic
cancer cells [16,17], in addition to its multiple actions as
an anti-metabolite, including inhibition of thymidylate
synthase, may provide an explanation for the clear bene-
fit of 5-FU based treatment in those patients with high
GST Pi (Figure 1). The additional generation of reactive
oxygen species by 5-FU may overwhelm the advantage
of high GST Pi in colon cancer cells either by directly
increasing the molecular species detoxified by GST Pi
enzyme activity and/or by depletion of the available pool
of GSH required for conjugation reactions performed by
GST enzymes. GSH is also the major anti-oxidant used
by cells in non-enzymatic reactions to protect against re-
active oxygen species.
Accordingly the implication of our finding is that stage
C colon cancer patients with low intracellular concen-
trations of GST Pi may not need to be treated with 5-
FU-based adjuvant chemotherapy whereas those with
high GST Pi definitely should be treated. As far as we
are aware, this is the first study to demonstrate the pre-
dictive value of GST Pi expression in regard to chemo-
therapy for stage C colon cancer.
A secondary finding was that GST Pi genotype had no
apparent influence on survival or on the association be-
tween survival and the joint effects of GST Pi expression
and adjuvant chemotherapy. Interest in the effect of
GST Pi polymorphisms arose from the concept that vari-
ant GST Pi proteins may differentially affect the actions
of chemotherapeutic drugs. The single nucleotide poly-
morphism A313G in exon 5 results in a valine for iso-
leucine substitution producing a Val/Val variant with
reduced GST Pi enzyme activity [18,19]. In metastatic
colorectal cancer Stoehlmacher et al. found poorer over-
all survival in patients with the Ile/Ile genotype than in
those with the Ile/Val or Val/Val genotypes after com-
bined 5-FU/oxaliplatin chemotherapy [9,20] although
this was not replicated by other researchers using the
same agents [21]. Also in 5-FU/oxaliplatin-treated
patients poorer survival was seen in those with the Ile/
Ile and Ile/Val genotypes compared with the Val/Val
genotype [22]. Similarly, significantly poorer survival
associated with the Ile/Ile genotype as compared with
the Ile/Val or Val/Val genotypes was reported in patients
treated with FOLFOX-4 [10], although two other studies
using FOLFOX showed no difference in survivalbetween genotypes [23,24]. Additionally, a study of oxa-
liplatin treatment [25] and two others using a mixture of
agents and regimens showed no differences between
GST Pi genotypes [11,26]. All of the above were prog-
nostic studies as all patients had received chemotherapy
and there was no random allocation to different treat-
ment groups. A truly predictive study that randomly
allocated patients to one of three 5-FU-based treatment
strategies also showed no differences between GST Pi
genotypes [27] while another study with patients rando-
mised to first-line capecitabine alone versus capecitabine
plus irinotecan showed a short, but significant improve-
ment in progression-free survival for the Val/Val geno-
type only [28]. Two remaining studies included patients
with colorectal tumours of all Dukes/TNM stages, not
just those with metastatic disease, but produced contra-
dictory results. Holley et al. found no association be-
tween GST Pi genotype and overall survival [29]
whereas Jones et al. found that the Ile/Ile genotype was
associated with decreased survival as compared with the
Ile/Val and Val/Val genotypes [30]. Thus the evidence
for an association between GST Pi genetic polymorph-
ism and chemotherapeutic treatment and survival (or
other patient outcomes) is inconclusive. The reasons
may relate to differing study designs; for example retro-
spective versus prospective, randomized versus non-ran-
domized allocation to treatment; varying stage mixes of
patients and hence different mixes of palliative and adju-
vant treatment; various chemotherapeutic agents and
regimens; and statistical issues such as limited numbers
of patients available for analysis. The latter is particularly
a problem in relation to the Val/Val genotype which has
a prevalence of only 8% to 10% which may lead to type
II errors in small patient samples.
A limitation of the present study is that patients were
not randomly allocated to the treatment and control
groups. Instead the treatment group comprised all
patients selected for chemotherapy since April 1992
when it became available in this hospital, whereas the
control patients were drawn from the period from 1979
to April 1992 and individually matched with treated
patients on age and sex. However there was no signifi-
cant difference between the treated group and the con-
trol group on 10 other background and tumour
pathology characteristics. Comorbidity may have influ-
enced survival and may have differed between the two
groups but we were unable to compare them because
details of comorbidity were not recorded in the database
until 1995. However, as the survival of patients with low
GST Pi did not differ significantly between the control
and treatment groups, it is most unlikely that differential
comorbidity could have accounted for the marked treat-
ment/control survival difference in patients with high
GST Pi alone. A further limitation was the relatively
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were 182 in total and 169 for the genotype analyses,
which may have limited our ability to find statistically
significant differences between some groups. Neverthe-
less the markedly poorer survival of the high GST Pi/
non-chemotherapy group (Figure 1) suggests that this
interaction would be likely to persist in a larger study.
Earlier studies of the association between GST Pi ex-
pression and patient outcomes have yielded varying
results. A significant independent association between
high GST Pi and diminished overall survival was found
by Mulder et al. and a similar independent association
was found by Sutoh et al. for disease-free survival [3,4];
both studies included colonic and rectal tumours and all
four Astler Coller or Dukes stages. Contrary to these
results Kim et al. found no association between GST Pi
expression and overall survival in patients with stage IV
colorectal cancer, all of whom had been treated by 5-
FU/oxaliplatin palliative chemotherapy [21]. Given that
tumour stage is the most clearly established prognostic
variable in colorectal cancer it is reasonable to expect
that other prognostic factors, including biomarkers, may
behave differently within different stages and also that
they may behave differently between the colon and rec-
tum or even at different sub-sites. In our study we fo-
cussed on stage C colonic tumours because of the
known beneficial effects of chemotherapy in this patient
group and the desire to find biomarkers which would
allow more refined targeting of patients most likely to
benefit from chemotherapy and to avoid costly and pos-
sibly toxic treatment of those who are unlikely to
benefit.
Conclusions
Survival did not differ between patients with low GST
Pi, whether or not they had chemotherapy and those
with high GST Pi who had chemotherapy, whereas
patients with high GST Pi who did not receive chemo-
therapy had markedly poorer survival than the other
three groups. GST Pi genotype was not associated with
survival and did not influence the relationship between
GST Pi expression, chemotherapy and survival. Given
that adjuvant chemotherapy is currently recommended
and routinely used in patients with stage C colon cancer
it is now unlikely, for ethical reasons, that a randomised
trial including a surgery-only control group could be
conducted to confirm our findings. However such a
study, based on an early randomized trial and archived
tissue, may be possible.
Methods
Information on patients having a resection for colorectal
cancer performed by members of the Concord Hospital
Department of Colorectal Surgery has been entered intoa prospective computer database since 1971 [31,32]. The
data set contains information on patient characteristics,
co-morbidity, presentation, investigations, surgical man-
agement, complications, adjuvant therapy, pathology and
follow-up, and has the approval of the South Western
Sydney Health Area Ethics Committee. All patients gave
written consent personally or through their guardian for
pathology specimens and anonymous clinical data to be
used for research purposes. From 1981, all resections
were performed by specialist colorectal surgeons accord-
ing to a standardized procedure [33] and acquisition of
clinical data has been conducted by a single surgeon (P.
C.). Patients reported here had a resection for clinico-
pathological stage C colon cancer between 1979 and
2004 inclusive.
Adjuvant chemotherapy
The chemotherapy regimens utilized involved, for the
most part, 6-month courses of bolus injections of 5-FU
and folinic acid administered daily for 5 days every
28 days over a total of 6 cycles (Mayo Clinic regimen
[34]) or 5-FU and leucovorin repeated weekly for 6
doses with a 2-week rest between (Roswell Park regimen
[35]). These regimens were used as they were supported
by results from randomized controlled trials on patients
with stage C colon cancer.
Selection of the historical control group
Patients who received adjuvant chemotherapy were
matched individually by sex and age with controls
selected from among patients who had a resection for
stage C colon cancer between 1979 and April 1992, be-
fore radiotherapy and chemotherapy were introduced at
this hospital [36]. Matching was by sex because numer-
ous studies have shown sex differences in many epi-
demiological, clinical and pathological characteristics of
colorectal cancer [37] and by age because of the demo-
graphic association between advancing age and dimin-
ishing survival in the population at large.
Histopathology
Pathological examination of the resected specimen fol-
lowed a standard protocol as described previously [38].
Only adenocarcinomas (including mucinous and signet
ring cell carcinomas) were included in the data set.
Where multiple tumours were present, only the lesion
with the most advanced stage was included. Tumour size
was measured as the greatest surface dimension. Blocks
were taken to demonstrate maximum direct tumour
penetration of the bowel wall. Additional blocks were
taken specifically to demonstrate the relationship be-
tween tumour and any adherent structure or tissue [39]
as well as lines of resection and the free serosal surface
[40]. Venous invasion by tumour referred to involvement
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bowel wall. When doubt existed as to whether a struc-
ture involved was a vein, a negative finding was recorded.
Tumour grade was assessed taking into account the de-
gree of differentiation and anaplasia, the nature of the
tumour margin (pushing or infiltrating) and the presence
and prominence of vascular invasion [31]. An apical
lymph node was defined as the most proximal of any
nodes found within 1 cm of the ligation of a named ves-
sel as the apex of a pedicle [41]. All pathological charac-
teristics analyzed were looked for in every specimen and
their presence or absence recorded explicitly. There were
no missing data on any original database variable.
Tumours were staged according to the Australian Clini-
copathological Staging System for colorectal cancer
which accommodates sub-stages compatible with other
clinicopathological staging systems such as Tumour
Nodes Metastases [42]. A stage C tumour was defined as
one with lymph node metastasis but no systemic metas-
tasis and no tumour present in the proximal, distal or
deep lines of resection histologically.Tissue microarray construction
Tissue micro arrays (TMA) for the assessment of GST
Pi were constructed using an Advanced Tissue Arrayer
ATA-100 (Chemicon, Temecula, Ca). 1.0 mm cores were
taken from carefully selected, morphologically represen-
tative areas of the original paraffin blocks and arrayed
into freshly made recipient paraffin blocks. As it is
known that there is heterogeneity within colorectal can-
cers, we took cores from (a) the central part of the
tumour, avoiding the luminal surface, the tumour edge
and areas of necrosis, (b) the deep invasive tumour front
at the interface between the tumour and non-neoplastic
tissue, and also (c) adjacent normal mucosa.Immunohistochemistry
GST Pi (1:20, Abcam, ab17088, Cambridge, U.K.) immu-
nohistochemistry was carried out using DAKO Autostai-
ner (DAKO, Glostrup, Denmark). Following dewaxing
and rehydration, antigen retrieval was performed in a
water bath (95°C) for 30 minutes using sodium citrate
(pH 6.0) Target Retrieval Solution S1699 (DAKO,
Glostrup, Denmark). Endogenous peroxidases were
blocked with 3% hydrogen peroxide for 5 minutes. Non-
specific binding sites were blocked with Protein Block
(DAKO, Glostrup, Denmark) for 10 minutes. The sec-
tions were incubated with diluted GST Pi antibody for 1
hour at room temperature, followed by secondary re-
agent EnVision +Dual Link System-HRP (DAB+) K4065
(DAKO, Glostrup, Denmark) for 30 minutes. Staining
was completed by a 10 minute incubation with 3,3-
diaminobenzidine (DAB+) substrate-chromogen. Afterbuffer wash the slides were counterstained with haema-
toxylin, dehydrated and mounted.
Immunohistochemical evaluation
Immunoreactivity for GST Pi was assessed independ-
ently by three experienced pathologists (K.T., C.F., C.C.)
who were unaware of the patients’ clinical characteris-
tics, other histopathological data and survival. Tissue
cores from the central part of the tumour and the inva-
sive front were assessed separately in each sample, as
was the presence of nuclear and cytoplasmic staining in
the tumour epithelial cells. The intensity of staining was
graded as 0 (no staining), 1 (weak staining), 2 (inter-
mediate staining), 3 (strong staining). The percentage of
stained cells (hereinafter termed “percentage stained”)
was recorded as a quasi-continuous variable coded 0%,
1%, 10%. . .90%, 100%. When there were discrepancies
between the observers, the slides were reviewed and a
consensus reached. To find the optimum dichotomy for
percentage stained in relation to survival the distribution
of percentage stained was first dichotomized at 0% ver-
sus 1–100% and survival curves with the associated p
value were obtained. The cutting point was then raised
in steps of 10% (0–9% vs. 10–100%, 0–20% vs. 30–100%
. . . 0–90% vs. 100%) and the separation of curves and p
value recorded at each step. This process yielded the
optimum cutting point giving the greatest separation of
survival curves [43].
Genotyping
Archival paraffin block sections of all the lymph nodes
resected from each patient were first reviewed by a path-
ologist (CC), who selected one normal cancer-free lymph
node from each patient for subsequent analysis. A core
biopsy was taken from the tissue block and DNA was
extracted with the Puregene DNA Isolation Kit (Gentra,
Minneapolis, MN) as previously described [44,45]. A
custom Taqman SNP Genotyping Assay (Applied Biosys-
tems, Foster City, CA) was used for genotyping. The pri-
mer and probe sequences for GSTP1 were as follows:
Forward primer 5′-CCTGGTGGACATGGTGAATG-3′;
Reverse primer 5′- TGGTGCAGATGCTCACATAGTTG-3′;
Probe 1 (VIC-labelled) 5′-TGCAAATACATCTCC-3′;
Probe 2 (FAM-labelled) 5′-CTGCAAATACGTCTCC-3′
[27].
The DNA samples were diluted to ~5 ng/ml and
tested in triplicate. Each 10μml reaction mix contained
5 μl of Taqman Universal PCR Master Mix (Applied
Biosystems), 2 μl of 5x SNP Genotyping Assay, and 3 μl
(~15 ng) of DNA. The PCR reactions and SNP analysis
were carried out on the ABI 7900 (Applied Biosystems),
with PCR conditions as follows: 50°C (2 min); 95°C
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(1 min).
Follow-up and survival
Apart from patients lost to follow-up, all patients were
followed annually until death or for up to 14 years or to
December 31, 2009. Overall survival time was measured
from resection until the date of death due to any cause,
the censoring date being the date of last follow-up for
those surviving or the date of last contact for those lost
to follow-up.
Statistical analysis
The chi-squared test or Fisher’s exact test were used to
examine the statistical significance of differences in pro-
portions. Comparisons of survival time between strata of
binary variables were made with the Kaplan-Meier
method and log-rank test. Proportional hazards regres-
sion and the Wald test were used in multivariable model-
ing with product terms to identify potential interactions.
The assumption of proportional hazards was assessed by
examining plots of log cumulative hazard for parallelism
and in no case was it materially violated in any variable
included in a regression model. The level for two-tailed
statistical significance was p# 0.05 with confidence inter-
vals (CI) at the 95% level. Analyses were performed with
SPSS 15.0 for Windows (SPSS Inc., Chicago, Il. USA).
Abbreviations
GST Pi: Glutathione S-transferase Pi; 5FU: 5-fluourouracil; GSH: The
nucleophilic thiol group of reduced glutathione.
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